<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946786</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-06-13</org_study_id>
    <nct_id>NCT04946786</nct_id>
  </id_info>
  <brief_title>Clinical, Biochemical and Body Composition Analysis in Assessment of Steatosis in Non Alcoholic Fatty Liver Disease</brief_title>
  <official_title>Role of Clinical, Biochemical and Body Composition Analysis in Assessment of Steatosis in Patients With Non Alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-alcoholic fatty liver disease (NAFLD) includes a spectrum of liver disorders&#xD;
      characterized by accumulation of hepatic fat in absence of significant alcohol consumption&#xD;
      (&lt;20 gm/day) and other causes of liver diseases. It is the most common cause of asymptomatic&#xD;
      elevation of liver enzymes worldwide (Marchesini et al., 2003).&#xD;
&#xD;
      Unfortunately, to date, existing non- or minimally invasive biomarkers are inadequate. While&#xD;
      a number of non- or minimally invasive tests are able to rule out ﬁbrosis or cirrhosis, no&#xD;
      single test to identify steatosis, to early diagnose NASH, or to predict the disease&#xD;
      progression is available. Moreover, specialized, combined tests are required to assess&#xD;
      treatment response in clinical trials on emerging compounds (Piazzolla and Mangia, 2020).&#xD;
&#xD;
      Among minimally invasive tools, plasma biomarkers and composite scores defined as &quot;wet&#xD;
      biomarkers&quot; are commonly used. For example, fasting insulin level and its use in measurement&#xD;
      of insulin resistance, Lipid Accumulation Product (LAP) score (Bedogni et al., 2010), the&#xD;
      NAFLD Liver Fat Score (NLFS) (Kontronen et al., 2009), Hepatic Steatosis Index (HSI) (Lee et&#xD;
      al., 2010), controlled attenuation parameter (CAP) measurement by fibroscan (Piazzolla and&#xD;
      Mangia, 2020). Recent studies have shown that CAP signiﬁcantly correlates with the percentage&#xD;
      of steatosis and steatosis grade and that median CAP is higher among patients with signiﬁcant&#xD;
      steatosis (Sasso et al., 2012 &amp; Karlas et al., 2017).&#xD;
&#xD;
      The prevalence of NAFLD is 80-90% in obese, 30-50% in patients with diabetes and up to 90% in&#xD;
      patients with hyperlipidemia (Abenavoli et al., 2014)&#xD;
&#xD;
      Central obesity or visceral fat (VF) (determined by waist circumference (WC)) is defined as&#xD;
      the presence of excess fat in the abdomen, and this type of obesity is often associated with&#xD;
      the development and progression of NAFLD or more advanced forms of liver disease (Abenavoli&#xD;
      et al., 2016). Thus, measurement of body composition rather than BMI may be helpful in the&#xD;
      prediction of NAFLD (Milić et al., 2014 and Abenavoli et al., 2016)&#xD;
&#xD;
      There is a growing need to assess the steatosis in NAFLD patients using minimally invasive&#xD;
      tools.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>studying anthropometric measurements of NAFLD cases.</measure>
    <time_frame>2 years</time_frame>
    <description>-study anthropometric measurements.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measurement of steatosis by fibroscan examination</measure>
    <time_frame>2 years</time_frame>
    <description>Fibroscan examination measuring control attenuation parameter &quot;CAP score&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>body muscle percentage</measure>
    <time_frame>2 years</time_frame>
    <description>measurement of body muscle percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>body fat percentage.</measure>
    <time_frame>2 years</time_frame>
    <description>measurement of body fat percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measurement of body water percentage.</measure>
    <time_frame>2 years</time_frame>
    <description>measurement of body water percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measuring serum cholesterol</measure>
    <time_frame>2 years.</time_frame>
    <description>measuring serum cholesterol by mg/ dl.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measuring serum triglycerides.</measure>
    <time_frame>2 years.</time_frame>
    <description>measuring serum triglycerides by mg/ dl.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measuring serum insulin level.</measure>
    <time_frame>2 years.</time_frame>
    <description>measuring of serum insulin level using ELISA kits</description>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease NAFLD</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Laboratory investigations, pelvi-abdominal US, fibroscan, and in body analysis</intervention_name>
    <description>Complete history taking.&#xD;
Thorough clinical examination :Assessing for buffalo hump, double chin, acanthosis nigricans, skin tags or acrochordon and xanthelasma and anthropometric measurements as measuring height &quot;m&quot;, weight &quot;Kg&quot;, waist circumference (WC) &quot;Cm&quot;, hip circumference (HC) &quot;Cm&quot;.&#xD;
3. Pelvi-abdominal ultrasound. 4. Fibroscan examination will be done for all subjects to assess steatosis by measuring the CAP score.&#xD;
5. Body composition analysis: to detect water, muscle and fat percentage in the body.&#xD;
6. Laboratory investigations:All samples wil be analyzed for fasting blood glucose (FBG), and post-prandial (2hrs after meals) blood glucose, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), very low-density lipoprotein (VLDL-C), alkaline phosphatase (ALK), aspartate transaminase (AST),alanine transaminase (ALT).&#xD;
• Fasting insulin levels will be measured using ELISA kits</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients: A total of 80 adult subjects will be included.&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
        Adult subjects with bright liver by abdominal ultrasound will be recruited for the study.&#xD;
        The diagnosis will be based on CAP score result measured by Fibroscan.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Adult subjects with bright liver by abdominal ultrasound will be recruited.&#xD;
&#xD;
          -  The diagnosis will be based on CAP score result measured by Fibroscan.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Alcohol consumption.&#xD;
&#xD;
          -  Patients with other liver diseases as acute and chronic viral hepatitis, autoimmune&#xD;
             hepatitis, primary biliary cirrhosis, drug-induced hepatitis.&#xD;
&#xD;
          -  Decompensated liver disease.&#xD;
&#xD;
          -  Other end organ failure.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Patients on statins or fenofibrate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Wafaa G Mohamed, Master</last_name>
    <phone>01111390732</phone>
    <email>wafaa_gamal_post@med.sohag.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ghada M Kamal, Professor</last_name>
  </overall_contact_backup>
  <reference>
    <citation>Abenavoli L, Di Renzo L, De Lorenzo A. Body Composition and Non-alcoholic Fatty Liver Disease. J Lifestyle Med. 2016 Mar;6(1):47-8. doi: 10.15280/jlm.2016.6.1.47. Epub 2016 Mar 31.</citation>
    <PMID>27358840</PMID>
  </reference>
  <reference>
    <citation>Abenavoli L, Milic N, Peta V, Alfieri F, De Lorenzo A, Bellentani S. Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World J Gastroenterol. 2014 Dec 7;20(45):16831-40. doi: 10.3748/wjg.v20.i45.16831. Review.</citation>
    <PMID>25492997</PMID>
  </reference>
  <reference>
    <citation>Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A; AlkaMeSy Study Group. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010 Apr;33(4):920-2. doi: 10.2337/dc09-1825. Epub 2010 Jan 12.</citation>
    <PMID>20067971</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 13, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Wafaa Gamal Mohamed</investigator_full_name>
    <investigator_title>priciple investigator</investigator_title>
  </responsible_party>
  <keyword>Non-alcoholic fatty liver disease NAFLD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

